期刊文献+

芪苈强心胶囊佐治慢性收缩性心力衰竭疗效观察 被引量:2

下载PDF
导出
摘要 目的观察芪苈强心胶囊佐治慢性收缩性心力衰竭(CHF)的临床疗效。方法将慢性CHF患者52例随机分为治疗组和对照组各26例。对照组予常规基础治疗,治疗组在常规治疗基础上加用芪苈强心胶囊。比较2组临床疗效、治疗前后血浆脑钠肽(BNP)水平及不良反应。结果治疗组总有效率为92.3%高于对照组的61.5%,差异有统计学意义(P<0.05)。2组治疗后BNP水平均降低,且治疗组低于对照组,差异均有统计学意义(P<0.05)。且2组均无严重不良反应发生。结论芪苈强心胶囊能明显改善慢性CHF患者的心功能。
作者 周加兴
出处 《临床合理用药杂志》 2012年第25期57-58,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献4

  • 1郑筱黄.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:129-134.
  • 2张子彬.充血性心力衰竭[M].北京:科学技术文献出版社,2002,5.54.
  • 3赖忠民.参附汤对慢性充血性心力衰竭患者左室收缩功能的影响.中国中西医结合杂志,1998,18(11):691-691.
  • 4郭进建,郭跃进,乔建峰.参附注射液对缺血性心肌病心功能和心肌纤维化的影响[J].福建中医学院学报,2006,16(4):4-6. 被引量:48

二级参考文献5

  • 1Task force for the diagnosis and treatment of chronic heart failure,European society of cardiology. Guidelines for the diagnosis and treatment of chronic heart failure [J]. Eur Heart J, 2001, 22(17):1527.
  • 2Lee DC, Johnson RA, Bingham JB, et at. Heart failure in out patients:A randomized trial of digoxin versus placebo[J]. N Engl J Med,1998,338(12):306.
  • 3Sedian R, Loebe M, Schmitt C, et al. Decreased plasma concentration of brain natriuretic peptide as a potential indicator of cardiac recovery in patients supported by mechanical circulatory assist systems [J]. J Am Coll Cardiol, 2001, 38(7):1942.
  • 4Klappacher G, Fransen P, Haab D, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis [J]. Am J Cardiol, 1995,75(14):913.
  • 5赖忠民.参附汤对慢性充血性心力衰竭病人左室收缩功能的影响[J].中国中西医结合杂志,1998,18(11):691-691.

共引文献133

同被引文献64

  • 1孙文娟,刘洁,曲少春,金毅,张志伟,李龙云.人参皂苷Rg_2对兔戊巴比妥钠心力衰竭的影响[J].中国现代应用药学,2004,21(6):447-450. 被引量:38
  • 2王继光,葛继勇.荟萃分析的价值与意义[J].中华高血压杂志,2007,15(5):355-357. 被引量:9
  • 3杨立波,高学东,谷春华,等.芪苈强心胶囊治疗慢性收缩性心力衰竭临床研究[A].络病学基础与临床研究(2)[C].第二届国际络病学大会论文集,2006:427.
  • 4苏慧敏.芪苈强心胶囊对慢性充血性心力衰竭病人生活质量的影响[J].中西医结合心脑血管病杂志,2007,5(10):917-918. 被引量:6
  • 5Troughton RW,Frampton CM,Yandle TG,et al. Treatment of heart failure guided by plasma aminoterminal brain nalriuretic peptide (N-BNP)concentrations [J]. Lancet, 2000,355(9210) : 1126-1130.
  • 6XIAO H, SONG Y, LI Y, et al. Qiliqiangxin regu- lates the balance between tumor necrosis factor-a and interleukin-10 and improves cardiac function in rats with myocardial infarction[J]. Cell Immunol, 2009, 260:51-55.
  • 7ZOU Y, LIN L, YE Y, et al. Qiliqiangxin inhibits the development of cardiac hypertrophy, remodeling, and dysfunction during 4 weeks of pressure overload in mice[J]. Cardiovasc Pharmacol, 2012, 59: 268 - 280.
  • 8LIU W, CHEN J, XU T, et al. Qiliqiangxin im- proves cardiac function in spontaneously hypertensive rats through the inhibition of cardiac chymase[J]. Am J Hypertens,2012,25 : 250- 260.
  • 9WEI Y, LIU X, HOU L, et al. Qiliqiangxin affects L type Ca2+ current in the normal and hypertrophied rat heart[J]. Evid Based Complement Ahernat Med, 2012,2012:131830.
  • 10LI X, ZHANG J, HUANG J, et al. A multicenter randomized double-blind parallel-group placebo-con- trolled study of the effects of qili qiangxin capsules in patients with chronic heart failure[J]. J Am Coll Car- diol,2013 : S0735.

引证文献2

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部